Glaukos (GKOS) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Glaukos (NYSE: GKOS):

• 7/13/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $164.00 price target on the stock.
• 7/8/2026 – Glaukos had its price target raised by Citigroup Inc. from $162.00 to $175.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Glaukos is now covered by HC Wainwright. They set a “buy” rating and a $168.00 price target on the stock.
• 7/6/2026 – Glaukos is now covered by HC Wainwright. They set a “buy” rating and a $168.00 price target on the stock.
• 7/4/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/1/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock.
• 6/21/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/17/2026 – Glaukos had its price target raised by Needham & Company LLC from $136.00 to $150.00. They now have a “buy” rating on the stock.
• 6/13/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/11/2026 – Glaukos had its price target raised by Citigroup Inc. from $140.00 to $162.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $162.00 price target on the stock.
• 5/30/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/26/2026 – Glaukos had its “outperform” rating reaffirmed by William Blair.
• 5/21/2026 – Glaukos had its price target raised by BTIG Research from $141.00 to $162.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the transaction, the director directly owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the transaction, the director owned 35,528 shares of the company’s stock, valued at $5,000,921.28. This trade represents a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 61,273 shares of company stock valued at $8,882,003. 5.90% of the stock is currently owned by company insiders.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.